Changes to the Code
H.R. 10227 · Improving Needed Safeguards for Users of Lifesaving Insulin Now Act of 2026 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
INSULIN Act of 2026
In committee · step 2 of 5
26 U.S.C. § 9815 Additional market reforms
1 change the bill asks for here, 1 carried out
- Carried out:
Section 9815(a)(1) of the Internal Revenue Code of 1986 is amended by inserting
and the INSULIN Act of 2026
afterAffordable Care Act
.
§ 9815(a)–(b)
§ 9815.1 Additional market reforms
(a) General rule Except as provided in subsection (b)—
(1) the provisions of part A of title XXVII of the Public Health Service Act (as amended by the Patient Protection and Affordable Care Act[inserted: and the INSULIN Act of 2026]) shall apply to group health plans, and health insurance issuers providing health insurance coverage in connection with group health plans, as if included in this subchapter; and
(2) to the extent that any provision of this subchapter conflicts with a provision of such part A with respect to group health plans, or health insurance issuers providing health insurance coverage in connection with group health plans, the provisions of such part A shall apply.
(b) Exception Notwithstanding subsection (a), the provisions of sections 2716 and 2718 of title XXVII of the Public Health Service Act (as amended by the Patient Protection and Affordable Care Act) shall not apply with respect to self-insured group health plans, and the provisions of this subchapter shall continue to apply to such plans as if such sections of the Public Health Service Act (as so amended) had not been enacted.
29 U.S.C. § 1185d Additional market reforms
1 change the bill asks for here, 1 carried out
- Carried out:
Section 715(a)(1) of the Employee Retirement Income Security Act of 1974 (29 U.S.C. 1185d(a)(1)) is amended by inserting
and the INSULIN Act of 2026
afterAffordable Care Act
.
§ 1185d(a)–(b)
§ 1185d. Additional market reforms
(a) General rule Except as provided in subsection (b)—
(1) the provisions of part A of title XXVII of the Public Health Service Act [42 U.S.C. 300gg et seq.] (as amended by the Patient Protection and Affordable Care Act[inserted: and the INSULIN Act of 2026]) shall apply to group health plans, and health insurance issuers providing health insurance coverage in connection with group health plans, as if included in this subpart; and
(2) to the extent that any provision of this part conflicts with a provision of such part A with respect to group health plans, or health insurance issuers providing health insurance coverage in connection with group health plans, the provisions of such part A shall apply.
(b) Exception Notwithstanding subsection (a), the provisions of sections 2716 and 2718 of title XXVII of the Public Health Service Act [42 U.S.C. 300gg–16, 300gg–18] (as amended by the Patient Protection and Affordable Care Act) shall not apply with respect to self-insured group health plans, and the provisions of this part shall continue to apply to such plans as if such sections of the Public Health Service Act (as so amended) had not been enacted.
42 U.S.C. § 262 Regulation of biological products
1 change the bill asks for here, 1 carried out
- Carried out:
Section 351(k) of the Public Health Service Act (42 U.S.C. 262(k)) is amended by adding at the end the following:
(10) Expediting biosimilar competition.— (A) In general.— The Secretary may, at the request of the sponsor of an application under this subsection for licensure of a biosimilar biological product that is designated as a competitive biosimilar biological product pursuant to …
§ 262(k)–(l)
Start of § 262 to (k)(9)(B) unchanged ·
(i) the biological product shall be immediately removed from such list for the same period as the revocation or suspension; and
(ii) a notice of the removal shall be published in the Federal Register.
(10) [inserted: Expediting biosimilar competition.—]
(A) [inserted: In general.—] [inserted: The Secretary may, at the request of the sponsor of an application under this subsection for licensure of a biosimilar biological product that is designated as a competitive biosimilar biological product pursuant to subparagraph (B), expedite the development and review of such application under this subsection.]
(B) [inserted: Designation process.—]
(i) [inserted: Request.—] [inserted: The sponsor of an application under this subsection may request the Secretary to designate the drug as a competitive biosimilar biological product. A request for such designation may be made concurrently with, or during the 60-day period immediately prior to, the submission of a biosimilar biological product license application under this subsection.]
(ii) [inserted: Criteria.—] [inserted: A biosimilar biological product is eligible for designation as a competitive biosimilar biological product under this paragraph if the Secretary determines that there is inadequate biosimilar competition.]
(iii) [inserted: Designation.—] [inserted: Not later than 60 calendar days after the receipt of a request under clause (i), the Secretary may—]
(I) [inserted: determine whether the biosimilar biological product that is the subject of the request meets the criteria described in clause (ii); and]
(II) [inserted: if the Secretary finds that such product meets such criteria, designate the biosimilar biological product as a competitive biosimilar biological product.]
(C) [inserted: Inadequate biosimilar competition.—] [inserted: In this paragraph, the term “inadequate biosimilar competition” means that, with respect to a biological product licensed under subsection (a)—]
(i) [inserted: on the list published under paragraph (9)(A) (not including biological products on the discontinued section of such list), there are fewer than 3 biological products licensed under this subsection pursuant to an application that uses such biological product licensed under subsection (a) as a reference product; and]
(ii) [inserted: not less than 3 years have passed since the expiration of all exclusivity periods applicable to such biological product licensed under subsection (a), or applicable to a biosimilar biological product licensed under this subsection using such biological product licensed under subsection (a) as a reference product, including any exclusivity periods under—]
(I) [inserted: paragraph (6);]
(II) [inserted: paragraph (7)(A);]
(III) [inserted: section 527 of the Federal Food, Drug, and Cosmetic Act; and]
(IV) [inserted: subsection (m).]
(l) Patents
(1) Confidential access to subsection (k) application
(A) Application of paragraph Unless otherwise agreed to by a person that submits an application under subsection (k) (referred to in this subsection as the “subsection (k) applicant”) and the sponsor of the application for the reference product (referred to in this subsection as the “reference product sponsor”), the provisions of this paragraph shall apply to the exchange of information described in this subsection.
Rest of § 262 unchanged ·
42 U.S.C. § 18022 Essential health benefits requirements
2 changes the bill asks for here, 2 carried out
- Carried out:
Section 1302(d)(2) of the Patient Protection and Affordable Care Act (42 U.S.C. 18022(d)(2)) is amended by adding at the end the following new subparagraph:
(D) Special rule relating to insulin coverage.— For plans years beginning on or after January 1, 2028, the exemption of coverage of selected insulin products (as defined in section 2729A of the Public Health Service Act) from the application of any deductible pursuant to section …
- Carried out:
Section 1302(e) of the Patient Protection and Affordable Care Act (42 U.S.C. 18022(e)) is amended by adding at the end the following:
(4) Coverage of certain insulin products.— (A) In general.— Notwithstanding paragraph (1)(B)(i), for plan years beginning on or after January 1, 2028, a health plan described in paragraph (1) shall provide coverage of selected insulin products, in accordance with section 2729A …
§ 18022(d)Levels of coverage(2)–(4)
Start of § 18022 to (d)(2)(A) unchanged ·
(B) Employer contributions The Secretary shall issue regulations under which employer contributions to a health savings account (within the meaning of section 223 of title 26) may be taken into account in determining the level of coverage for a plan of the employer.
(C) Application In determining under this title,1 the Public Health Service Act [42 U.S.C. 201 et seq.], or title 26 the percentage of the total allowed costs of benefits provided under a group health plan or health insurance coverage that are provided by such plan or coverage, the rules contained in the regulations under this paragraph shall apply.
(D) [inserted: Special rule relating to insulin coverage.—] [inserted: For plans years beginning on or after January 1, 2028, the exemption of coverage of selected insulin products (as defined in section 2729A of the Public Health Service Act) from the application of any deductible pursuant to section 2729(a)(1) of such Act, shall not be treated as increasing the actuarial value of a plan when determining the actuarial value of a qualified health plan under this subsection.]
(3) Allowable variance The Secretary shall develop guidelines to provide for a de minimis variation in the actuarial valuations used in determining the level of coverage of a plan to account for differences in actuarial estimates.
(4) Plan reference In this title,1 any reference to a bronze, silver, gold, or platinum plan shall be treated as a reference to a qualified health plan providing a bronze, silver, gold, or platinum level of coverage, as the case may be.
§ 18022(e)–(g)
(e) unchanged ·
(ii) section 5000A(e)(5) of such title (relating to individuals with hardships).
(3) Restriction to individual market If a health insurance issuer offers a health plan described in this subsection, the issuer may only offer the plan in the individual market.
(4) [inserted: Coverage of certain insulin products.—]
(A) [inserted: In general.—] [inserted: Notwithstanding paragraph (1)(B)(i), for plan years beginning on or after January 1, 2028, a health plan described in paragraph (1) shall provide coverage of selected insulin products, in accordance with section 2729A of the Public Health Service Act, before an enrolled individual has incurred, during the plan year, cost-sharing expenses in an amount equal to the annual limitation in effect under subsection (c)(1) for the plan year.]
(B) [inserted: Terminology.—] [inserted: For purposes of subparagraph (A)—]
(i) [inserted: the term “selected insulin products” has the meaning given such term in section 2729A(b) of the Public Health Service Act; and]
(ii) [inserted: the requirements of section 2729A of such Act shall be applied by deeming each reference in such section to “individual health insurance coverage” to be a reference to a plan described in paragraph (1).]
(f) Child-only plans If a qualified health plan is offered through the Exchange in any level of coverage specified under subsection (d), the issuer shall also offer that plan through the Exchange in that level as a plan in which the only enrollees are individuals who, as of the beginning of a plan year, have not attained the age of 21, and such plan shall be treated as a qualified health plan.
(g) Payments to Federally-qualified health centers If any item or service covered by a qualified health plan is provided by a Federally-qualified health center (as defined in section 1396d(l)(2)(B) of this title) to an enrollee of the plan, the offeror of the plan shall pay to the center for the item or service an amount that is not less than the amount of payment that would have been paid to the center under section 1396a(bb) of this title) for such item or service.